Table 1.
Participant demographics at study enrollment by vaccine type.
| Vaccine type | ||||||
|---|---|---|---|---|---|---|
| Total (n = 655) | BNT162b2 (n = 306) | mRNA-1273 (n = 247) | ChAdOx1+mRNA (n = 102) | p-value | ||
| Age at enrollment, median [Q1,Q3] | 63 [51,72] | 71 [55,77] | 62 [51,68] | 50 [33,58] | <0.001 | |
| Age group, n (%) | ||||||
| <65 | 353 (53.9) | 104 (34.0) | 147 (59.5) | 102 (100.0) | <0.001 | |
| 65–74 | 157 (24.0) | 75 (24.5) | 82 (33.2) | |||
| ≥75 | 145 (22.1) | 127 (41.5) | 18 (7.3) | |||
| Sex, n (%) | ||||||
| Male | 286 (43.7) | 157 (51.3) | 117 (47.4) | 12 (11.8) | <0.001 | |
| Female | 369 (56.3) | 149 (48.7) | 130 (52.6) | 90 (88.2) | ||
| Vaccine-priority group, n (%) | ||||||
| Individuals at increased risk | 194 (29.9) | 165 (54.3) | 29 (11.9) | <0.001 | ||
| General population | 329 (50.7) | 118 (38.8) | 211 (86.8) | |||
| Health-care workers | 126 (19.4) | 21 (6.9) | 3 (1.2) | 102 (100.0) | ||
| CCI, n (%) | ||||||
| 0 | 497 (75.9) | 191 (62.4) | 207 (83.8) | 99 (97.1) | <0.001 | |
| 1–2 | 123 (18.8) | 85 (27.8) | 35 (14.2) | 3 (2.9) | ||
| >2 | 35 (5.3) | 30 (9.8) | 5 (2.0) | |||
| Comorbidities in the previous 5 years, n | ||||||
| Myocardial infarction | 8 | <5* | 5 | 0.346 | ||
| Congestive heart failure | 18 | 13 | 5 | 0.049 | ||
| Peripheral vascular disease | 6 | 5 | <5* | 0.268 | ||
| Cerebrovascular disease | 20 | 13 | 7 | 0.080 | ||
| Dementia | ||||||
| Chronic pulmonary disease | 30 | 19 | 9 | <5* | 0.167 | |
| Rheumatological disease | 13 | 9 | <5* | <5* | 0.377 | |
| Peptic ulcer disease | <5* | <5* | <5* | 1.000 | ||
| Mild liver disease | 14 | 13 | <5* | 0.002 | ||
| Diabetes without chronic complications | 20 | 13 | 7 | 0.080 | ||
| Diabetes with chronic complications | <5* | <5* | <5* | 1.000 | ||
| Hemiplegia or paraplegia | ||||||
| Any malignancy, including leukemia and lymphoma | 82 | 62 | 20 | <0.001 | ||
| Moderate or severe liver disease | 5 | <5* | <5* | 0.471 | ||
| Metastatic solid tumor | <5* | <5* | 0.166 | |||
| AIDS/HIV | 11 | 8 | <5* | 0.196 | ||
| Renal disease | 10 | 10 | 0.003 | |||
| Organ transplantation | 38 | 35 | <5* | <0.001 | ||
*Groups with small numbers (<5 participants per cell) where there is the potential that individual participants could be identified or be able to identify themselves have been edited to maintain participant confidentiality.